natgillin/translations-raw huggingface dataset:
This subgroup of patients is considered to constitute the core efficacy population. 
Ta podskupina bolnikov predstavlja glavno populacijo, pri kateri je bila učinkovitost največja.
• Paxene is not recommended for use in children and adolescents under 18 years. 
• Zdravila Paxene ni priporočljivo uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
In the study, the majority of patients were administered granulocyte colony stimulating factor (G-CSF). 
V študiji so večini bolnikov dali granulocitne kolonije stimulirajoči faktor (G-CSF).
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
Znotraj vsake skupine pogostnosti so neželeni učinki predstavljeni v padajoči resnosti.
Dispose of any remaining contents after first use. 
Preostalo vsebino zavrzite po prvi uporabi.
Limited efficacy data supports this indication (see section 5.1). 
Omejeni podatki o učinkovitosti podpirajo to indikacijo (glejte poglavje 5.1).
Based on in vitro studies, the degree of plasma protein binding has been reported to range from 88 to 98 %. 
Na osnovi študij in vitro so poročali, da je stopnja vezave na plazemske beljakovine med 88 in 98 %.
Gastrointestinal 
Gastrointestinalni
Date of latest renewal: 19th July 2009 
Datum podaljšanja: 19. julij 2009.
Infections and infestations 
Infekcije in infestacije
The amount of alcohol in this medicinal product may alter the effects of other medicines. 
Količina alkohola v tem zdravilu lahko spremeni učinek drugih zdravil.
If necessary, your doctor will adjust the dosage during the treatment. 
Vaš zdravnik bo med zdravljenjem po potrebi prilagodil odmerek.
The carcinogenic potential of paclitaxel has not been studied. 
Karcinogenega potenciala paklitaksela niso preučevali.
• Eating disorders including anorexia 
• motnje prehranjevanja vključno z anoreksijo
If you see another doctor or visit a hospital, remember to tell them what medicines you are taking. 
Če boste obiskali drugega zdravnika ali bolnišnico, mu morate povedati, katera zdravila prejemate.
The median time to progression in the core population was 468 days (95 % CI 257-NE). 
Srednja vrednost do stopnjevanja pri glavni populaciji je bila 468 dni (95 % CI 257-NE).
Concurrent, serious, uncontrolled infections. 
Sočasne, resne, nenadzorovane okužbe.
As the AIDS-KS population is very specific, safety data from a clinical study of 107 AIDS-KS patients are presented separately at the end of this section. 
Populacija bolnikov z AIDS-KS je zelo specifična, zato so podatki o varnosti iz klinične študije 107 bolnikov z AIDS-KS predstavljeni ločeno na koncu tega poglavja.
• Loosening of finger and toe nails - you should wear protection on your feet and hands when exposed to the sun 
• zrahljanje nohtov na rokah in nogah - nositi morate zaščito rok in nog, če jih izpostavljate soncu
• The levels of some enzymes in your blood might rise 
• v krvi se lahko povečajo ravni nekaterih encimov
To help prevent allergic reactions occurring while you are receiving your infusion you will be given medication before your treatment starts. 
Da bi preprečili alergijske reakcije, ki se lahko pojavijo med dajanjem infuzije, boste pred začetkom zdravljenja prejeli nekatera zdravila.
Pharmacotherapeutic group: taxanes, ATC code: L01CD01. 
Farmakoterapevtska skupina: taksani, oznaka ATC: L01C D01
Like other genotoxic cytostatics, paclitaxel can have genotoxic effects. 
Podobno drugim genotoksičnim citostatikom, ima lahko paclitaxel genotoksične učinke.
This reaction should be considered in the differential diagnosis of cases of severe or persistent diarrhoea occurring during or shortly after treatment with paclitaxel. 
Omenjeno reakcijo je treba upoštevati pri diferencialni diagnostiki primerov s hudo ali perzistirajočo diarejo, ki se pojavi med ali le kratek čas po zdravljenju s paklitakselom.
Stabilisation results in the inhibition of the normal dynamic reorganisation of the microtubular network that is essential for vital interphase and mitotic cellular functions. 
Zaradi stabilizacije je zavrta normalna dinamična reorganizacija mreže mikrotubulov, ki je bistvenega pomena pri ključnih celičnih funkcijah v interfazi in mitozi.
The amounts (dose) of Paxene you will be given will be worked out depending on your body surface area in square meters (m2) and will also take into account the results of your blood tests and your medical condition. 
Količino (odmerek) zdravila Paxene, ki jo boste prejeli bodo določili glede na vašo telesno površino, izraženo v kvadratnih metrih (m2), in ob upoštevanju rezultatov krvnih preiskav ter vašega zdravstvenega stanja.
The amount of alcohol in this medicine may alter the effects of other medicines and should be taken into account in patients with liver disease or epilepsy. 
Količina alkohola v tem zdravilu lahko spremeni učinek drugih zdravil, kar je treba upoštevati pri zdravnikih z obolelimi jetri ali z epilepsijo.
Of the 107 patients, 63 patients were considered resistant to liposomal anthracyclines. 
Od 107 je bilo 63 bolnikov odpornih proti liposomskim antraciklinom.
Further data on the potential of drug interactions between paclitaxel and other CYP 3A4 substrates/inhibitors are limited. 
Nadaljnji podatki o morebitnih interakcijah med paklitakselom in drugimi substrati/zaviralci CYP 3A4 so omejeni.
• If you are taking other medicines which could interact with paclitaxel (see Using other medicines). 
• Če jemljete druga zdravila, ki bi lahko medsebojno delovala s paklitakselom (glejte Uporaba drugih zdravil).
In spite of this high protein binding, paclitaxel is widely distributed to tissues. 
Kljub visoki vezanosti na beljakovine se paklitaksel široko porazdeljuje v tkiva.
The other most commonly reported nervous system disorder is somnolence, which affected 14 % of patients. 
Druga bolezen živčnega sistema o kateri se najpogostejše poroča je zaspanost, ki je prizadela 14 % bolnic.
• Acute leukaemia (blood cancer) 
• akutna levkemija (krvni rak)
Your concentrate for solution for infusion will be kept in the pharmacy and they will prepare it, ready to be given by the doctor or nurse. 
Vaš koncentrat za raztopino za infundiranje bodo shranjevali v lekarni in ga zdravniku ali medicinski sestri pripravili za uporabo.
Pre-existing neuropathies resulting from prior therapies are not a contraindication for paclitaxel therapy. 
Obstoječe nevropatije, ki so posledica prejšnjih zdravljenj, niso kontraindikacija za zdravljenje s paklitakselom.
Half to one hour before your infusion you will be given two different types of injection (an antihistamine and an H2 antagonist). 
Pol ure do eno uro pred infuzijo boste prejeli še dve vrsti injekcij (antihistaminik in antagonist receptorjev H2).
Clear, colourless to slightly yellow, viscous solution. 
Bistra, brezbarvna do rahlo rumena viskozna tekočina.
The incidence of Grade 4 neutropenia lasting 7 days or more was 22 %. 
Incidenca nevtropenije 4. stopnje, ki je trajala sedem dni ali več, je bila 22-odstotna.
Neutropenia resolved in 35 days in all patients who were followed. 
Nevtropenija je pri vseh zdravljenih bolnikih izginila v 35 dneh.
Important information about some of the ingredients of Paxene 
Pomembne informacije o nekaterih sestavinah zdravila Paxene
Red cell transfusions were required in 21 % of patients. 
Pri 21 % bolnikov je bila potrebna transfuzija rdečih krvnih celic.
In addition, paclitaxel induces bundles of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. 
Poleg tega paklitaksel inducira nastanek snopov mikrotubulov v celotnem celičnem ciklu ter oblikovanje multiplih aster mikrotubulov v času mitoze.
London E16 2QJ United Kingdom. 
London E16 2QJ Velika Britanija.
Your concentrate for solution for infusion will be diluted and given slowly into a vein over about 3 hours unless otherwise stated. 
Koncentrat za raztopino za infundiranje bodo najprej razredčili in vam ga nato v 3 urah počasi dali v veno, razen če ni drugače navedeno.
- Keep this leaflet safe as you may need to read it again. 
Morda ga boste želeli ponovno prebrati.
The results obtained with Paxene are closely similar to those of published paclitaxel Phase III trials. 
Rezultati, dobljeni pri uporabi zdravila Paxene, so zelo podobni objavljenim iz III. faze preskušanj paklitaksela.
Since elimination of doxorubicin and its active metabolites may be reduced when paclitaxel and doxorubicin are used in combination, paclitaxel should be administered 24 hours after doxorubicin. 
Ker se eliminacija doksorubicina in njegovih aktivnih metabolitov lahko zmanjša, kadar se paklitaksel in doksorubicin uporabljata skupaj, naj se paklitaksel uporabi šele 24 ur po doksorubicinu.
Arthralgia was reported in 32 % of all patients (5 % severe) and myalgia in 47 % (6 % severe). 
O artralgiji so poročali pri 32 % vseh bolnikov (5 % huda) in o mijalgiji pri 47 % (6 % huda).
Paraesthesia was observed in 48 % of patients. 
Parestezijo so opazili pri 48 % bolnikov.
Paclitaxel, particularly in combination with radiation of the lung and/or gemcitabine, irrespective of their chronological order, may contribute to the development of interstitial pneumonitis. 
Paklitaksel, zlasti v kombinaciji z obsevanjem pljuč in/ali gemcitabinom, ne glede na časovno zaporedje, lahko prispeva k razvoju intersticialnega pnevmonitisa.
• are taking ritonavir, nelfinavir, efavirenz, nevirapine (for the treatment of AIDS) or any other prescribed medicines for your condition; 
• jemljete ritonavir, nelfinavir, efavirenz, nevirapin (za zdravljenje AIDS-a) ali katerokoli drugo zdravilo, ki so vam ga predpisali za vašo bolezen;
The disposition of paclitaxel is non-linear (concentration dependent) as the systemic exposure increases more than expected following an increase in dosage. 
Izpostavljenost paklitakselu je nelinearna (odvisna od koncentracije), ker se s povečevanjem odmerka sistemska izpostavljenost poveča bolj, kot bi pričakovali.
There is no known specific treatment for extravasation reactions. 
Specifično zdravljenje za reakcije ekstravazacije ni poznano.
Twelve and then six hours before your infusion you will be given dexamethasone (a steroid), either as a tablet to swallow or as an injection. 
Dvanajst in nato šest ur pred infuzijo boste prejeli deksametazon (steroid) v obliki tablete ali injekcije.
If you have a history of heart problems, your heart rate may be monitored. 
Če ste kdaj imeli težave s srcem, bodo morda spremljali tudi vaš srčni utrip.
Use by: 
Uporabno do:
Since Paxene contains ethanol, consideration should be given to possible central nervous system and other effects. 
Ker vsebuje zdravilo Paxene etanol, je treba upoštevati možnost učinka na osrednji živčni sistem in druge učinke.
Minor symptoms such as flushing or skin reactions do not require interruption of therapy. 
Blagi simptomi, kot sta rdečica ali kožne reakcije, ne zahtevajo prekinitve zdravljenja.
• Balance problems 
• težave z ravnotežjem
Very rare*: atrial fibrillation 
Zelo redki*: atrijska fibrilacija
• If you previously had radiation treatment (radiotherapy) to your chest (see section 4: Possible side effects). 
• Če so vas zdravili z obsevanjem (radioterapijo) prsnega koša (glejte poglavje 4: Možni neželeni učinki).
The exact mechanism of the antitumour activity of paclitaxel is not known. 
Natančen mehanizem protitumornega delovanja paklitaksela ni znan.
If you are already being treated with doxorubicin for your condition, then your first dose of paclitaxel should be given 24 hours after doxorubicin. 
Ce se z doksorubicinom že zdravite zaradi vašega stanja, potem morate prvi odmerek paklitaksela prejeti 24 ur po doksorubicinu.
Common: severe elevation in transaminases, severe elevation in alkaline phosphatase 
Pogosti: hud dvig vrednosti transaminaz, hud dvig vrednosti alkalne fosfataze
Where event incidence differed between Paxene and other paclitaxel clinical studies, the most frequent incidence is presented. 
Kadar se pogostost dogodka pri študijah zdravila Paxene in drugih kliničnih študijah paklitaksela razlikuje, je navedena največja pogostost.
• Loss of balance or staggering 
• izguba ravnotežja ali nestabilnost
Further instructions for preparation for infusion 
Dodatna navodila za pripravo infuzije
In liposomal anthracycline-resistant patients, the response rates were comparable for patients who had never received a protease inhibitor (55.6 %) and those who received one at least 2 months prior to treatment with Paxene (60.9 %). 
Pri bolnikih, odpornih proti liposomskim antraciklinom, so bile stopnje odzivnosti primerljive s stopnjami pri tistih bolnikih, ki niso nikoli prejemali proteaznih inhibitorjev (55,6 %), in pri tistih, ki so ga prejeli vsaj dva meseca pred zdravljenjem z zdravilom Paxene (60,9 %).
However, paclitaxel belongs to a class of substances which are potentially carcinogenic based on their mechanism of action. 
Vendar pa sodi paklitaksel v skupino snovi, ki so zaradi svojega mehanizma delovanja potencialno karcinogene.
• Advanced ovarian cancer or remaining tumour (> 1 cm) after initial surgery, in combination with cisplatin as first-line treatment. 
• napredovalega karcinoma jajčnikov ali preostalega tumorja (> 1 cm) po začetni operaciji, v kombinaciji s cisplatinom kot zdravljenje prvega izbora
Paxene belongs to a group of medicines known as antineoplastic agents. 
Zdravilo Paxene sodi v skupino zdravil, znanih kot antineoplastična zdravila.
Patients with hepatic impairment may be at increased risk of toxicity, particularly Grade 3-4 myelosuppression. 
Bolniki z jetrno okvaro so lahko v nevarnosti za zastrupitev, še posebej v primeru mielosupresije 3.-4. stopnje.
There is no evidence that the toxicity of paclitaxel is increased when given as a 3 hour infusion to patients with mildly abnormal liver function. 
Ni dokazov o tem, da se toksičnost paklitaksela zveča pri dajanju 3 urne infuzije pri bolnikih z rahlo neobičajno jetrno funkcijo.
This may be a sign of a serious bowel inflammation (pseudomembranous colitis). 
To je namreč lahko znak resnega vnetja črevesja (psevdomembranski kolitis).
Pseudomembranous colitis has been rarely reported including cases in patients who have not been concomitantly treated with antibiotics. 
O psevdomembranskem kolitisu so poročali redko, vključno s primeri bolnikov, ki sočasno niso prejemali antibiotikov.
Like all medicines, Paxene can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Paxene neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
This is a tumour that arises from blood vessels in the skin or internal organs and typically appears as flat or raised, purple to dark brown patches on the skin. 
To je tumor, ki izvira iz krvnih žil v koži ali notranjih organih in se običajno pojavi kot ploska ali izbočena, temno rdeča do rjava zaplata na koži
WHAT PAXENE IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO PAXENE IN ZA KAJ GA UPORABLJAMO
Safety and efficacy in children and adolescents (under 18 years) has not been established. 
Varnost in učinkovitost zdravila pri otrocih in mladostnikih (mlajših od 18 let) ni znana, zato paklitaksela pri teh bolnikih ni priporočljivo uporabljati.
It is generally believed that paclitaxel promotes the assembly of microtubules from tubulin dimer and prevents depolymerisation. 
V splošnem velja, da pospešuje tvorbo mikrotubulov iz dimerov tubulina in preprečuje njihovo depolimerizacijo.
Concurrent administration of ketoconazole, a known potent inhibitor of CYP 3A4, does not inhibit the elimination of paclitaxel in patients; thus, both medicinal products may be administered together without dosage adjustment. 
Sočasno dajanje ketokonazola, znanega zaviralca CYP 3A4, pri bolnikih ne zavre eliminacije paklitaksela, zato lahko obe zdravili dajemo sočasno brez prilagoditve odmerka.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2) 
Izdaja zdravila je le pod omejenimi pogoji in na recept (Glejte Dodatek I: Povzetek glavnih značilnosti zdravila, poglavje 4.2)
• Effects on the nerves controlling your muscles resulting in weakness in the arms and legs 
• učinek na živce, ki nadzirajo mišice, kar povzroči oslabelost rok in nog
Other in-use storage times and conditions are the responsibility of the user. 
Drugačni časi in pogoji shranjevanja zdravila po prvem odpiranju so odgovornost uporabnika.
Animal studies showed non-reversible, toxic effects on the male reproductive organs at clinically relevant exposure levels. 
Študije na živalih kažejo pri klinično pomembnih nivojih izpostavljenosti nepovratne toksične učinke zdravila na reproduktivne organe pri moških.
If severe peripheral neuropathy occurs the benefit of continued treatment should be weighed against the risks. 
Če se pojavi huda periferna nevropatija, je potrebno pretehtati koristi nadaljnjega zdravljenja v primerjavi z možnimi tveganji.
• Appearing and acting confused 
• zmedena pojava in ravnanje
London E16 2QJ United Kingdom 
London E16 2QJ Velika Britanija
If any problems occur while you are having your infusion, the medical staff will be on hand to take any necessary action. 
Če boste med infundiranjem imeli kakšne težave, vam bo za ustrezno ukrepanje na voljo zdravstveno osebje.
Dose adjustments during treatment 
Prilagoditev odmerjanja med zdravljenjem
Paxene may alter the effect of other medicines because of its high alcohol content. 
Zdravilo Paxene lahko zaradi velike vsebnosti alkohola spremeni učinek drugih zdravil.
Recommendations for handling 
Priporočila za rokovanje z zdravilom
• Problems with your lungs including swelling and fluid accumulation, which may cause breathing problems 
• težave s pljuči, vključni z otekanjem in nabiranjem tekočine, ki lahko povzročijo težave z dihanjem
Renal excretion plays a minor role in the elimination of paclitaxel, less than 10 % of the dose has been reported to be excreted in the urine as unchanged drug. 
Ekskrecija preko ledvic igra pri izločanju paklitaksela majhno vlogo; poročali so, da se manj kot 10 % odmerka izloči v nespremenjeni obliki z urinom.
Median survival for Paxene could not be computed, but the lower 95 % bound was 617 days in core patients. 
Srednje vrednosti preživetja pri uporabi zdravila Paxene ni bilo mogoče določiti, sicer pa je bila pri glavni skupini bolnikov spodnja meja 95-odstotna, torej 617 dni.
Except for haematological and hepatic events (see below), generally the frequency and severity of undesirable effects in AIDS-KS patients were similar to those noted in patients with other solid tumours treated with paclitaxel monotherapy. 
Razen hematoloških učinkov in učinkov na jetra (glejte spodaj), sta bili pogostost in resnost neželenih učinkov pri bolnikih z AIDS-KS podobni kot pri bolnikih z drugimi trdnimi tumorji, ki so jih samostojno zdravili s paklitakselom.
You will only be given your infusion under medical supervision, and you will be checked regularly while you are having your infusion to see how you are reacting to it. 
Infuzijo boste prejeli pod zdravniškim nadzorom, kjer bodo med infundiranjem redno preverjali, kako se odzivate na zdravljenje.
If you feel unwell between courses or after your treatment has finished, tell your doctor or pharmacist as soon as you can. 
Če se slabo počutite med dvema cikloma zdravljenja ali po koncu zdravljenja, o tem čimprej obvestite svojega zdravnika ali farmacevta.
• Before you start treatment with Paxene and during treatment, you will have regular blood tests to check that it is safe for you to continue with your treatment. 
• Pred začetkom zdravljenja z zdravilom Paxene in med zdravljenjem vam bodo redno pregledovali kri, da bi ugotovili, ali je nadaljevanje zdravljenja za vas varno.
The efficacy and safety of Paxene were investigated in a single, non-comparative study in 107 patients with advanced KS, previously treated with systemic chemotherapy. 
Učinkovitost in varnost zdravila Paxene so raziskovali v eni sami, neprimerjalni študiji na 107 bolnikih z napredovalim Kaposijevim sarkomom, ki so se prej zdravili s sistemsko kemoterapijo.
Anaemia (Hb< 11 g/dl) was observed in approximately 9 % of treated patients but was severe in less than 1 % (Hb< 8 g/dl). 
Anemijo (Hb < 11 g/dl) so opazili pri približno 9 % zdravljenih bolnikov, vendar je bila pri manj kot 1 % (Hb < 8 g/dl) huda.
Paxene concentrate for solution for infusion is used to treat: 
Zdravilo Paxene koncentrat za raztopino za infundiranje se uporablja za zdravljenje:
• Low blood platelet counts that can cause unusual bleeding (e.g. nose bleeds) and unexplained bruising 
• nizka raven trombocitov, ki lahko povzroči neobičajno krvavitev (npr. krvavitev iz nosu) in nerazložljive modrice
As Paxene contains ethanol (392 mg/ml), possible effects on the CNS and other effects should be considered (see section 4.7). 
Zdravilo Paxene vsebuje etanol (392 mg/ml), zato je treba upoštevati morebitne učinke na osrednje živčevje in druge učinke (glejte poglavje 4.7).
Paxene solutions should be prepared and stored in glass, polypropylene, or polyolefin containers. 
Raztopine zdravila Paxene je potrebno pripraviti in shranjevati v vsebnikih iz stekla, polipropilena ali poliolefina.
Clearance was 20.6 l/h/m2 (range 11 - 38) and the volume of distribution was 291 l/m2 (range 121 - 638). 
Očistek je bil 20,6 l/h/m2 (v intervalu 11 - 38), volumen porazdelitve pa 291 l/m2 (v intervalu 121 - 638).
Paclitaxel at low doses of 0.6 mg/kg/day was associated with low fertility and foetal toxicity in rats. 
Pri podganah je bil paklitaksel pri nizkih odmerkih 0,6 mg/kg/dan povezan z zmanjšano plodnostjo in pojavom toksičnosti pri plodu.
Paxene might also leak from the vein and cause an infection or ulceration of the surrounding skin. 
Zdravilo Paxene lahko izteka tudi iz vene in povzroči okužbo in razjede okoliške kože.
Paxene is indicated for the treatment of patients with: - advanced AIDS-related Kaposi's sarcoma (AIDS-KS) who have failed prior liposomal anthracycline therapy; - metastatic carcinoma of the breast (MBC) who have failed, or are not candidates for standard anthracycline-containing therapy; - advanced carcinoma of the ovary (AOC) or with residual disease (> 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment; - metastatic carcinoma of the ovary (MOC) after failure of platinum-containing combination therapy without taxanes as second-line treatment; - non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin. 
Zdravilo Paxene je indicirano za zdravljenje bolnikov z: - napredovalim Kaposijevim sarkomom, povezanim z AIDS (AIDS-KS), pri katerih je bilo predhodno zdravljenje z antraciklini v obliki liposomov neuspešno, - metastatskim karcinomom dojke (metastatic breast cancer - MBC), pri katerih je bilo standardno zdravljenje z antraciklini neuspešno ali pa tovrstno zdravljenje za njih ni primerno, - napredovalim karcinomom jajčnikov (advanced carcinoma of the ovary - AOC) ali z rezidualno boleznijo (> 1 cm) po prvotni lapratomiji, v kombinaciji s cisplatinom kot zdravljenje prvega izbora, - metastatskim karcinomom jajčnika (metastatic ovarian cancer - MOC) po neuspešnem kombiniranem zdravljenju s platino, ki ne vključuje taksanov zdravljenje drugega izbora, - nedrobnoceličnim karcinomom pljuč (non-small cell lung carcinoma - NSCLC), ki niso kandidati za potencialno zdravilni operacijski poseg in/ali zdravljenje z obsevanjem, v kombinaciji s cisplatinom.
Handling and disposal 
Ravnanje in odlaganje
• Severe chest pains, irregular heart beat, feeling faint and heart attack 
• hude bolečine v prsih, nepravilen srčni ritem, občutek omedlevanja in srčni napad
Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Zelo pogosti (≥ 1/10); pogosti (≥ 1/100, < 1/10); občasni (≥ 1/1 000, < 1/100); redki (≥ 1/10 000, < 1/1 000); zelo redki (< 1/10 000), vključno s posameznimi primeri.
When administered as part of a combination regimen with cisplatin, it is recommended that Paxene is given before cisplatin. 
Kadar ga uporabljamo kot del kombiniranega zdravljenja s cisplatinom, je priporočeno zdravilo Paxene dajati pred cisplatinom.